HUMALOG MIX 50/50 KWIKPEN (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
HUMALOG MIX 50/50 KWIKPEN is a rapid-acting insulin analog combining insulin lispro in a 50/50 premixed formulation for subcutaneous injection. It treats both Type 1 and Type 2 Diabetes Mellitus by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. The mechanism mimics the body's natural insulin response to lower blood glucose levels.
This mature, LOE-approaching product faces significant competitive pressure (score: 30/100) and declining relevance, signaling smaller brand teams and reduced commercial investment.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 50/50 KWIKPEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHUMALOG MIX 50/50 currently shows zero linked job openings, reflecting a mature product with contracted commercial infrastructure. Career opportunities on this product are primarily in defensive sales and market access roles focused on formulary maintenance rather than growth expansion.